Leggett Thomas 4

What Happened

• Thomas Leggett, Chief Financial Officer of Stoke Therapeutics, reported the exercise/conversion of a derivative (reported as code M) that resulted in the acquisition of 14,750 shares on March 15, 2026. The filing also shows a corresponding disposition entry of 14,750 shares (reported as a derivative) on the same date. The reported price for both entries is $0.00, consistent with the conversion/settlement of restricted stock units (RSUs) rather than a cash purchase or market sale.

Key Details

• Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (timely within required reporting window).
• Shares acquired: 14,750 at $0.00 (conversion/exercise of a derivative/RSU).
• Shares disposed: 14,750 at $0.00 (reported as derivative disposition).
• Shares owned after transaction: Not specified in this filing.
• Footnotes: F1 — each RSU equals a contingent right to one share upon settlement; F2 — the award vests 1/4 annually beginning March 15, 2026, subject to continued service.
• Transaction codes: M = exercise/conversion of a derivative; disposal listed as derivative. No 10b5-1 plan or tax-withholding details were reported in this Form 4.

Context

• This appears to be a routine conversion/settlement of equity awards (RSUs) under the company’s compensation plan, not an open-market buy or sell. The $0.00 price signals settlement of awards rather than a cash transaction. Such award settlements are common for executives and do not by themselves indicate a buy/sell market signal.